ReviewThe Lancet. Rheumatology2021
The role of antirheumatics in patients with COVID-19.
Review in The Lancet. Rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- The relationship between respiratory tract infections caused by toxin-producing bacteria in burn patients during COVID-19: pathogenesis, diagnostics and novel therapies.Journal of medical microbiology · 2025Review
- Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders.European journal of pediatrics · 2023Review
- Fatal rhabdomyolysis caused by COVID-19 infection: a case report.Annals of medicine and surgery (2012) · 2023Article
- COVID-19: A Possible Contribution of the MAPK Pathway.Biomedicines · 2023Article
- Cross-sectional study of COVID-19 infection in patients with rheumatic diseases in a sample of a Damascene population, Syria.Annals of medicine and surgery (2012) · 2023Article
- A comprehensive review of COVID-19 symptoms and treatments in the setting of autoimmune diseases.Virology journal · 2023Review
- A natural goldmine of binding proteins and soluble receptors simplified their translation to blockbuster drugs, all in one decade.Frontiers in immunology · 2023Review
- Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry.Clinical rheumatology · 2022Observational
- Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses.Brain : a journal of neurology · 2022Article
- [Pituitary and COVID-19: review].Problemy endokrinologii · 2022Review
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
- Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.Nature reviews. Rheumatology · 2022Review
- Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.Frontiers in pharmacology · 2022Article
- Coronavirus Infection 2019 (COVID-19) and Autoimmunity.Herald of the Russian Academy of Sciences · 2022Article
- Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.Rheumatology (Oxford, England) · 2021Review
- Strategies to protect surfactant and enhance its activity.Biomedical journal · 2021Review
- Clinical features and outcome of MIS-C patients: an experience from Central Anatolia.Clinical rheumatology · 2021Article
- Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases.The Lancet. Rheumatology · 2021Article
- First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea.The Lancet. Rheumatology · 2021Article
- Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has resulted in more than 2 million deaths globally. Two interconnected stages of disease are generally recognised; an initial viral stage and a subsequent immune response phase with the clinical characteristics of hyperinflammation associated with acute respiratory distress syndrome. Therefore, many immune modulators and immunosuppressive drugs, which are widely used in rheumatological practice, have been proposed as treatments for patients with moderate or severe COVID-19. In this Review, we provide an overview of what is currently known about the efficacy and safety of antirheumatic therapies for the treatment of patients with COVID-19. Dexamethasone has been shown to reduce COVID-19 related mortality, interleukin-6 inhibitors to reduce risk of cardiovascular or respiratory organ support, and baricitinib to reduce time to recovery in hospitalised patients requiring oxygen support. Further studies are needed to identify whether there is any role for glucocorticoids in patients with less severe COVID-19. Although evidence on the use of other antirheumatic drugs has suggested some benefits, results from adequately powered clinical trials are urgently needed. The heterogeneity in dosing and the absence of uniform inclusion criteria and defined stage of disease studied in many clinical trials have affected the conclusions and comparability of trial results. However, after the success of dexamethasone in proving the anti-inflammatory hypothesis, the next 12 months will undoubtedly bring further clarity about the clinical utility and optimal dose and timing of other anti-rheumatic drugs in the management of COVID-19.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.